biostudies-literatureUnknown16Ismail FSImplications of glia in the pathophysiology of epilepsy raise the question of how these cells besides neurons are responsive to antiseizure medications (ASMs). Understanding ASM effects on glia and glia-mediated inflammation may help to explore astrocytes and microglia as potential targets for alternative anti-epileptogenic therapies. The aim of this study was to investigate the effects of the new generation ASM brivaracetam (BRV) in an astrocyte-microglia co-culture model of inflammation. Primary rat astrocytes co-cultures containing 5%-10% (M5, "physiological" conditions) or 30%-40% (M30, "pathological inflammatory" conditions) of microglia were treated with different concentrations of BRV (0.5, 2, 10, and 20 μg/ml) for 24 h. Glial cell viability was measured by MTT assay. Microglial actFrontiers in cellular neuroscience995861https://www.ebi.ac.uk/biostudies/studies/S-EPMC9670320biostudies-literatureBrivaracetam exhibits mild pro-inflammatory features in an <i>in vitro</i> astrocyte-microglia co-culture model of inflammation.PMC9670320Kummel MLFaustmann PMForster EFaustmann TJCorvace FIsmail FSfalseBrivaracetam exhibits mild pro-inflammatory features in an <i>in vitro</i> astrocyte-microglia co-culture model of inflammation.Implications of glia in the pathophysiology of epilepsy raise the question of how these cells besides neurons are responsive to antiseizure medications (ASMs). Understanding ASM effects on glia and glia-mediated inflammation may help to explore astrocytes and microglia as potential targets for alternative anti-epileptogenic therapies. The aim of this study was to investigate the effects of the new generation ASM brivaracetam (BRV) in an astrocyte-microglia co-culture model of inflammation. Primary rat astrocytes co-cultures containing 5%-10% (M5, "physiological" conditions) or 30%-40% (M30, "pathological inflammatory" conditions) of microglia were treated with different concentrations of BRV (0.5, 2, 10, and 20 μg/ml) for 24 h. Glial cell viability was measured by MTT assay. Microglial act2022-01-01T00:00:00Z20222025-04-21T14:13:02.858Z2025-04-21T14:13:02.858ZS-EPMC96703203640675310.3389/fncel.2022.995861